Manny Simons, Akouos CEO (Webb Chappell/Harvard Business School)
October 18, 2022 07:33 AM EDTUpdated 10:05 AM
Deals
Cell/Gene Tx

Up­dat­ed: Not known for gene ther­a­py plays, Eli Lil­ly ac­quires hear­ing loss start­up Ak­ou­os for $487M plus CVR

Max Gelman

Senior Editor

Eli Lil­ly is jump­ing in­to gene ther­a­pies for the ear.

The Big Phar­ma an­nounced ear­ly Tues­day that it will ac­quire Boston biotech Ak­ou­os for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times